Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexaria Bioscience (LEXX) Retained Earnings (2016 - 2026)

Lexaria Bioscience's Retained Earnings history spans 12 years, with the latest figure at -$55444.0 for Q1 2026.

  • Quarterly results put Retained Earnings at -$55444.0 for Q1 2026, up 53.11% from a year ago — trailing twelve months through Feb 2026 was -$55444.0 (up 53.11% YoY), and the annual figure for FY2025 was -$70335.0, up 99.86%.
  • Retained Earnings for Q1 2026 was -$55444.0 at Lexaria Bioscience, up from -$65.1 million in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of -$55444.0 in Q1 2026 to a low of -$65.1 million in Q4 2025.
  • The 5-year median for Retained Earnings is -$44.5 million (2023), against an average of -$38.9 million.
  • The sharpest move saw Retained Earnings fell 25.46% in 2022, then soared 99.86% in 2025.
  • Year by year, Retained Earnings stood at -$40.9 million in 2022, then dropped by 14.9% to -$46.9 million in 2023, then fell by 15.59% to -$54.3 million in 2024, then fell by 19.89% to -$65.1 million in 2025, then soared by 99.91% to -$55444.0 in 2026.
  • According to Business Quant data, Retained Earnings over the past three periods came in at -$55444.0, -$65.1 million, and -$70335.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.